The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 31, 2023

Filed:

Oct. 11, 2018
Applicant:

Galapagos NV, Mechelen, BE;

Inventors:

Steven Emiel Van Der Plas, Mechelen, BE;

Oscar Mammoliti, Mechelen, BE;

Sébastien Laurent Xavier Martina, Mechelen, BE;

Pieter Isabelle Roger Claes, Gentbrugge, BE;

Ghjuvanni Petru Diunisu Coti, Mechelen, BE;

Denis Maurice Annoot, Romainville, FR;

Miriam López Ramos, Romainville, FR;

René Alexandre Galien, Romainville, FR;

David Amantini, Romainville, FR;

Reginald Christophe Xavier Brys, Mechelen, BE;

Assignee:

GALAPAGOS NV, Mechelen, BE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61P 37/06 (2006.01); A61P 35/00 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/5355 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/5355 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01); C07B 2200/05 (2013.01);
Abstract

The present invention discloses compounds according to Formula I: Wherein R, L, R, L, R, Cy, and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IFNα, IL12 and/or IL23 by administering the compound of the invention.


Find Patent Forward Citations

Loading…